Ceftazidime | CAS#72558-82-8 | β-lactam antibiotic

MedKoo Cat#: 317451 | Name: Ceftazidime

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ceftazidime is a third-generation cephalosporin antibiotic with potent activity against a broad range of Gram-negative bacteria, including Pseudomonas aeruginosa. Its antibacterial action is mediated by inhibition of bacterial cell wall synthesis via high affinity binding to penicillin-binding proteins (PBPs). Ceftazidime exhibits minimum inhibitory concentrations (MICs) typically ranging from 0.25 to 8 µg/mL for susceptible strains of Escherichia coli, Klebsiella pneumoniae, and P. aeruginosa, with an MIC90 of ~4 µg/mL against many Enterobacteriaceae. It is ineffective against most Gram-positive bacteria and anaerobes. Resistance is primarily mediated by extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamase overexpression. Ceftazidime has been widely used for serious infections such as nosocomial pneumonia, bacteremia, and urinary tract infections, often in hospitalized settings. Note: This product contains 10% sodium carbonate.

Chemical Structure

Ceftazidime

CAS#72558-82-8 (free)

Theoretical Analysis

MedKoo Cat#: 317451

Name: Ceftazidime

CAS#: 72558-82-8 (free)

Chemical Formula: C22H22N6O7S2

Exact Mass: 0.0000

Molecular Weight: 546.58

Elemental Analysis: C, 48.34; H, 4.06; N, 15.38; O, 20.49; S, 11.73

Price and Availability

Size	Price	Availability
100mg	USD 90.00	Ready to ship
250mg	USD 150.00	Ready to ship
500mg	USD 225.00	Ready to ship
1g	USD 350.00	Ready to ship
2g	USD 550.00	Ready to ship
5g	USD 950.00	2 weeks
10g	USD 1,450.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

72558-82-8 (free) 73547-70-3 (2HCl) 73547-61-2 (sodium) 78439-06-2 (free and hydrate)

Synonym

Ceftazidime anhydrous; Ceftazidime Pentahydrate; Fortaz; Fortum; GR 20263; GR-20263; GR20263; LY 139381; LY-139381; LY139381; Tazidime

IUPAC/Chemical Name

(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

InChi Key

ORFOPKXBNMVMKC-LGJNPRDNSA-N

InChi Code

InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13+

SMILES Code

CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-]

Appearance

Solid powder

Purity

>90% (contain 10% Na2CO3)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch, Lot#T23C06I26

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 546.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Jones TE, Selby PR, Mellor CS, Cheam DB. Ceftazidime stability and pyridine toxicity during continuous i.v. infusion. Am J Health Syst Pharm. 2019 Feb 1;76(4):200-205. doi: 10.1093/ajhp/zxy035. Review. PubMed PMID: 30715181. 2: Das S, Li J, Riccobene T, Carrothers TJ, Newell P, Melnick D, Critchley IA, Stone GG, Nichols WW. Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia. Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02187-18. doi: 10.1128/AAC.02187-18. Print 2019 Apr. Review. PubMed PMID: 30670413; PubMed Central PMCID: PMC6437548. 3: Giri P, Patel H, Srinivas NR. Review of Clinical Pharmacokinetics of Avibactam, A Newly Approved non-β lactam β-lactamase Inhibitor Drug, In Combination Use With Ceftazidime. Drug Res (Stuttg). 2019 May;69(5):245-255. doi: 10.1055/a-0748-5548. Epub 2018 Oct 8. Review. PubMed PMID: 30296806. 4: Sy SKB, Zhuang L, Sy S, Derendorf H. Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development. Clin Pharmacokinet. 2019 May;58(5):545-564. doi: 10.1007/s40262-018-0705-y. Review. PubMed PMID: 30097887. 5: Zhong H, Zhao XY, Zhang ZL, Gu ZC, Zhang C, Gao Y, Cui M. Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2018 Oct;52(4):443-450. doi: 10.1016/j.ijantimicag.2018.07.004. Epub 2018 Aug 31. Review. PubMed PMID: 30012440. 6: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK501420/ PubMed PMID: 30000480. 7: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK500953/ PubMed PMID: 30000012. 8: Shirley M. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections. Drugs. 2018 Apr;78(6):675-692. doi: 10.1007/s40265-018-0902-x. Review. PubMed PMID: 29671219. 9: Sherry N, Howden B. Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam - epidemiology, laboratory detection and treatment implications. Expert Rev Anti Infect Ther. 2018 Apr;16(4):289-306. doi: 10.1080/14787210.2018.1453807. Epub 2018 Mar 21. Review. PubMed PMID: 29543500. 10: Rodriguez BA, Girotto JE, Nicolau DP. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children. Curr Pediatr Rev. 2018;14(2):97-109. doi: 10.2174/1573396314666180308150908. Review. PubMed PMID: 29521242. 11: Falcone M, Viale P, Tiseo G, Pai M. Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia. Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):331-340. doi: 10.1080/17425255.2018.1434142. Epub 2018 Jan 31. Review. PubMed PMID: 29373935. 12: Tuon FF, Rocha JL, Formigoni-Pinto MR. Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review. Infection. 2018 Apr;46(2):165-181. doi: 10.1007/s15010-017-1096-y. Epub 2017 Nov 7. Review. PubMed PMID: 29110143. 13: Yaeger A, Kappes J. Pharmacotherapy Review of Ceftazidime-Avibactam. S D Med. 2017 May;70(5):229-231. Review. PubMed PMID: 28813756. 14: Barber KE, Ortwine JK, Akins RL. Ceftazidime/Avibactam: Who Says You Can't Teach an Old Drug New Tricks? J Pharm Pharm Sci. 2016 Oct - Dec;19(4):448-464. doi: 10.18433/J3X31R. Review. PubMed PMID: 28057163. 15: Goodlet KJ, Nicolau DP, Nailor MD. Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections. Ther Clin Risk Manag. 2016 Dec 1;12:1811-1826. eCollection 2016. Review. PubMed PMID: 27942218; PubMed Central PMCID: PMC5140030. 16: Buckman SA, Krekel T, Muller AE, Mazuski JE. Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections. Expert Opin Pharmacother. 2016 Dec;17(17):2341-2349. Epub 2016 Oct 31. Review. PubMed PMID: 27758148. 17: Hidalgo JA, Vinluan CM, Antony N. Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. Drug Des Devel Ther. 2016 Jul 26;10:2379-86. doi: 10.2147/DDDT.S110946. eCollection 2016. Review. PubMed PMID: 27528799; PubMed Central PMCID: PMC4970634. 18: Falcone M, Paterson D. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother. 2016 Oct;71(10):2713-22. doi: 10.1093/jac/dkw239. Epub 2016 Jul 17. Review. PubMed PMID: 27432599. 19: van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. Clin Infect Dis. 2016 Jul 15;63(2):234-41. doi: 10.1093/cid/ciw243. Epub 2016 Apr 20. Review. PubMed PMID: 27098166; PubMed Central PMCID: PMC4928383. 20: Gardiner BJ, Golan Y. Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections. Expert Rev Anti Infect Ther. 2016;14(5):451-63. doi: 10.1586/14787210.2016.1173542. Review. PubMed PMID: 27042762.

View History

Azoprocarbazine

MedKoo CAT#: 575237

CAS#: 2235-59-8